Douglas Robinson

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

Gabriel N. Hortobágyi, David Chen, Martine Piccart et al. · Journal of Clinical Oncology · 2015 · 245 citations · Full text

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

Fabrice André, Sara A. Hurvitz, Angelica Fasolo et al. · Journal of Clinical Oncology · 2016 · 165 citations

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

Fei Huang, Ann Greer, Warren Hurlburt et al. · Cancer Research · 2008 · 163 citations · Full text

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Kevin B. Kim, Jason Chesney, Douglas Robinson et al. · Clinical Cancer Research · 2011 · 121 citations · Full text

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Barbara Pistilli, Timothy Pluard, Ander Urruticoechea et al. · Breast Cancer Research and Treatment · 2017 · 63 citations · Full text

Breast Oncology, Medicine, Pharmacology +7